The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Investor visas a gold mine for private credit
Finance

Investor visas a gold mine for private credit

More than $55m committed for residency destined for credit funds which lend to NZ firms.

Aussie broker giant CBN enters NZ with Folio deal
Finance

Aussie broker giant CBN enters NZ with Folio deal

CBN is backed by ASX-listed Steadfast Group.

John Anthony 11 Aug 2025
Capital gains tax to solve house-price affordability crisis?
Finance

Capital gains tax to solve house-price affordability crisis?

ANZ's Richard Yetsenga said house-price affordability is a significant challenge. 

Staff reporters 07 Aug 2025
Surcharge ban may not be a win for consumers
Finance

Peter Griffin: Surcharge ban may not be a win for consumers

There are winners and losers in the surcharge move.

Peter Griffin 30 Jul 2025